Oghenowede Eyawo

Oghenowede Eyawo

Auto-generated profile, based on publicly available information

Oghenowede Eyawo

School of Global Health, Faculty of Health, York University, Toronto, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in The American Journal of Medicine
Verified
Journal Article
Closed access
EMEdward Mills
Edward Mills
OEOghenowede Eyawo
Oghenowede Eyawo
ILIan Lockhart
Ian Lockhart
SKSteven Kelly
Steven Kelly
PWPing Wu
Ping Wu
JEJon O. Ebbert
Jon O. Ebbert

1 December 2019 in The Lancet HIV
Verified
Journal Article
Open access
TFTahvi D Frank
Tahvi D Frank
ACAustin Carter
Austin Carter
DJDeepa Jahagirdar
Deepa Jahagirdar
MBMolly H Biehl
Molly H Biehl
DDDirk Douwes-Schultz
Dirk Douwes-Schultz
CMChristopher J L Murray
Christopher J L Murray
Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980-2017 and forecast these estimates to 2030 for 195 countries and territories. We determined a modelling strategy for each country on the basis of the availability and quality of data. For countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source version of the Estimation and Projection Package-a natural history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up and new infections. Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87-2·04) and has since decreased to 0·95 million deaths (0·91-1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 2·79-3·67) and since then have gradually decreased to 1·94 million (1·63-2·29) in 2017. These trends, along with ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8-39·2) people living with HIV in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets. Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, combined with the current context of stagnated funding for related interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention initiatives that can be scaled up to have population-level impact. Bill & Melinda Gates Foundation, National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH.

7 October 2010 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
EME. J. Mills
E. J. Mills
PWP. Wu
P. Wu
GCG. Chong
G. Chong
IGI. Ghement
I. Ghement
SSSonal Singh
Sonal Singh
MBMatthias Briel
Matthias Briel
Background: Statins represent the largest selling class of cardiovascular drug in the world. Previous randomized trials (RCTs) have demonstrated important clinical benefits with statin therapy. Aim: We combined evidence from all RCTs comparing a statin with placebo or usual care among patients with and without prior coronary heart disease (CHD) to determine clinical outcomes. Design: We searched independently, in duplicate, 12 electronic databases (from inception to August 2010), including full text journal content databases, to identify all statin versus inert control RCTs. We included RCTs of any statin versus any non-drug control in any populations. We abstracted data in duplicate on reported major clinical events and adverse events. We performed a random-effects meta-analysis and meta-regression. We performed a mixed treatment comparison using Bayesian methods. Results: We included a total of 76 RCTs involving 170 255 participants. There were a total of 14 878 deaths. Statin therapy reduced all-cause mortality, Relative Risk (RR) 0.90 [95% confidence interval (CI) 0.86–0.94, P ≤ 0.0001, I 2 = 17%]; cardiovascular disease (CVD) mortality (RR 0.80, 95% CI 0.74–0.87, P < 0.0001, I 2 = 27%); fatal myocardial infarction (MI) (RR 0.82, 95% CI 0.75–0.91, P < 0.0001, I 2 = 21%); non-fatal MI (RR 0.74, 95% CI 0.67–0.81, P ≤ 0.001, I 2 = 45%); revascularization (RR 0.76, 95% CI 0.70–0.81, P ≤ 0.0001); and a composite of fatal and non-fatal strokes (0.86, 95% CI 0.78–0.95, P = 0.004, I 2 = 41%). Adverse events were generally mild, but 17 RCTs reported on increased risk of development of incident diabetes [Odds Ratio (OR) 1.09; 95% CI 1.02–1.17, P = 0.001, I 2 = 11%]. Studies did not yield important differences across populations. We did not find any differing treatment effects between statins. Discussion: Statin therapies offer clear benefits across broad populations. As generic formulations become more available efforts to expand access should be a priority.

16 October 2019 in Nature
Verified
Journal Article
Open access
PDF file
RBRoy Burstein
Roy Burstein
NHNathaniel J Henry
Nathaniel J Henry
MCMichael L Collison
Michael L Collison
LMLaurie B Marczak
Laurie B Marczak
ASAmber Sligar
Amber Sligar
SHSimon Hay
Simon Hay
Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations.

5 April 2014 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
KJKarissa M Johnston
Karissa M Johnston
KGKatherine Gooch
Katherine Gooch
EKEllen Korol
Ellen Korol
PVPamela Vo
Pamela Vo
OEOghenowede Eyawo
Oghenowede Eyawo
ALAdrian Levy
Adrian Levy
Background: Preterm birth is a major risk factor for morbidity and mortality among infants worldwide, and imposes considerable burden on health, education and social services, as well as on families and caregivers. Morbidity and mortality resulting from preterm birth is highest among early (< 28 weeks gestational age) and moderate (28–32 weeks) preterm infants, relative to late preterm infants (33–36 weeks). However, substantial societal burden is associated with late prematurity due to the larger number of late preterm infants relative to early and moderate preterm infants. Methods: The aim in this study was to characterize the burden of premature birth in Canada for early, moderate, and late premature infants, including resource utilization, direct medical costs, parental out-of-pocket costs, education costs, and mortality, using a validated and published decision model from the UK, and adapting it to a Canadian setting based on analysis of administrative, population-based data from Québec. Results: Two-year survival was estimated at 56.0% for early preterm infants, 92.8% for moderate preterm infants, and 98.4% for late preterm infants. Per infant resource utilization consistently decreased with age. For moderately preterm infants, hospital days ranged from 1.6 at age two to 0.09 at age ten. Cost per infant over the first ten years of life was estimated to be $67,467 for early preterm infants, $52,796 for moderate preterm infants, and $10,010 for late preterm infants. Based on population sizes this corresponds to total national costs of $123.3 million for early preterm infants, $255.6 million for moderate preterm infants, $208.2 million for late preterm infants, and $587.1 million for all infants. Conclusion: Premature birth results in significant infant morbidity, mortality, healthcare utilization and costs in Canada. A comprehensive decision-model based on analysis of a Canadian population-based administrative data source suggested that the greatest national-level burden is associated with moderate preterm infants due to both a large cost per infant and population size while the highest individual-level burden is in early preterm infants and the largest total population size is in late preterm infants. Although the highest medical costs are incurred during the neonatal period, greater resource utilization and costs extend into childhood.

1 November 2010 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
OEOghenowede Eyawo
Oghenowede Eyawo
DWDamien de Walque
Damien de Walque
NFNathan Ford
Nathan Ford
GGGloria Gakii
Gloria Gakii
RLRichard T Lester
Richard T Lester
EMEdward J Mills
Edward J Mills